Executive Officers

Jeffrey Yam, 29
Chief Executive Officer and President

Jeffrey Yam is currently an executive director at Integrated Capital (Asia) Limited, a Hong Kong-based multi-strategy private investment firm, leading all private equity and venture capital investments since January 2017 as well as the firm’s expansion into Southeast Asia and India. He is a member of the board of directors of Forbes Global Media Holdings Limited (Forbes Media) and has been leading its strategic investment initiative since September 2017. Forbes Media is a world-leading business media brand that published content globally via digital channels and print. He is also a member of the board of directors for Pomona Acquisition Limited (Nasdaq: PMAC), a SPAC formed for the purpose of acquiring a target in the FinTech sector, which is currently seeking to be listed on Nasdaq. Prior to joining Integrated Capital, Mr. Yam worked in the investment banking division at BNP Paribas in Hong Kong from 2015 to 2016, where he worked on initial public offerings and mergers and acquisitions. Prior to joining BNP Paribas, Mr. Yam worked at the private banking division of Credit Suisse in Hong Kong in 2015. Mr. Yam holds a Bachelor of Science in Business Administration, Cum Laude, from Boston University Questrom School of Business, majoring in finance.

Kelvin Sze, 39
Chief Financial Officer and Chairman of the Board

Kelvin Sze is currently the chief financial officer of Pomona Acquisition Limited (Nasdaq: PMAC), a SPAC formed for the purpose of acquiring a target in the FinTech sector, which is currently seeking to be listed on Nasdaq. He has approximately 18 years of experience in asset management, hedge funds and leading investment banks across various investment products in global markets. He was most recently head of macro-trading in Hong Kong at Barclays, where he also served as an executive officer for the Hong Kong Monetary Authority regulated activities, managing the bank’s offshore North Asian emerging markets trading businesses, from 2015 to 2021. From 2013 to 2015, he managed the Asia macro fund for Trinitus Asset Management in Hong Kong, trading primarily currency and interest rate derivatives, corporate cash bonds, and equity derivatives. Before Trinitus, Mr. Sze was a market maker at Bank of America’s and Merrill Lynch’s emerging market fixed-income, currencies and interest rate derivatives in Hong Kong and New York from 2007 to 2013. He started his career at BlackRock in 2003 as an investment analyst, where he was responsible for portfolio analytics, market risk management, and quantitative investment strategies in alternative investments in New York. Mr. Sze is also a director of several investment holding companies which have no current business activities, including Astral Merit Limited, Power Wealth Development Limited and EFFIONE, Inc. Mr. Sze holds a Bachelor of Science degree in Operations Research and Industrial Engineering from Cornell University and is a Chartered Financial Analyst (CFA) charterholder. He is also a member of Central4Change, a nonprofit organization focused on empowering local youth in Hong Kong.

Board of Directors

Dr. Hoon K. Lee, 48
Independent Director 

Dr. Lee is a radiation oncologist in Staten Island, New York, who has been in practice for over 17 years. He is the recipient of the Gilbert H. Fletcher Award, the Thomas Barkley Award, and the Jay and Lori Eisenberg Endowed Fellowship at the M.D. Anderson Cancer Center. He is also a recipient of the Roentgen Research Award from the Radiological Society of North America. He has presented at international and national conferences such as the Radiation Therapy Oncology Group, American Radium Society, American Society for Therapeutic Radiology and Oncology, American Society of Clinical Oncology Prostate Cancer Symposium, and the Radiological Society of North America. From 2006 to 2010, Dr. Lee served on the American College of Radiology Appropriateness Criteria Expert Panel on radiation oncology lung work group. He served as guest reviewer for the journal of International Journal of Radiation Oncology, Biology, Physics from 2002 to 2014. He is board-certified in radiation oncology by the American College of Radiology, and is on the medical staff at Richmond University Medical Center in New York (RUMC). Prior to joining RUMC, Dr. Lee was employed at Regional Imaging & Therapeutic Radiology Services, P.C. Staten Island (Regional Radiology) as a radiation oncologist from 2004 to 2016. From 2007 to 2020, Dr. Lee was also a general partner of Regional Bard Realty, an entity which owned the real estate where Regional Radiology practiced. Dr. Lee is also board-certified in Radiation Oncology by the American Board of Radiology. He is also a member of the American Medical Association, American Society of Clinical Oncology, and American Society for Radiation Oncology. Dr. Lee earned his Bachelor of Arts in molecular and cell biology with honors from the University of California at Berkeley. He obtained his medical doctorate from the George Washington University School of Medicine in 1999. He completed his residency at the University of Texas, M.D. Anderson Cancer Center. He completed his training in radiation oncology at The University of Texas — M.D. Anderson Cancer Center in 2004.

Louis S. Villalba, 53
Independent Director 

Mr. Villalba has more than 25 years of industry experience in developing and commercializing innovative therapie. Mr. Villalba is the chief executive officer of Genea Biomedx, which is part of the fertility group Genea and focuses on developing fertility technologies, since 2018. Mr. Villalba was previously with OvaScience from 2015 to 2018, where he served as executive vice president of the corporate development and successfully managed the firm’s exit into a reverse merger. Prior to OvaScience, Mr. Villalba was chief business officer at Evofem from 2014 to 2015, global vice president of sales at Auxogyn from 2013 to 2014 and executive vice president of Europe for Conceptus from 2004 to 2013 where he was part of the team that completed the $1.1B sale of the company to Bayer AG. Mr. Villalba holds a Bachelor of Science in Business Management from Menlo College.

Frank Sun, 45
Independent Director 

Mr. Sun has over 15 years of experience in the pharmaceutical and health investment industry. From February 2020 to May 2021, Mr. Sun served as executive director and vice chairman to the board of Shenzhen Hepalink Pharmaceutical Co. Ltd. (Hepalink), and was primarily responsible for the major decision-making of Hepalink and oversaw Hepalink’s strategic investments, the management of its investments and new product development, capital market strategies, financing activities, and investors relationship. From March 2020 to May 2021, Mr. Sun was the executive chairman of Cytovance Biologics, where he was responsible for the overall strategy and supervision of execution of the company’s business. From December 2017 to January 2020, Mr. Sun was a managing director of Yunfung Capital Co., Ltd. responsible for healthcare investments. From 2006 to August 2017, Mr. Sun worked in the investment banking division of UBS AG in New York and Hong Kong, including as a managing director from February 2016 to August 2017, and head of Asia Healthy Group from October 2015 to August 2017. He served as an equity research analyst in Morgan Stanley & Co. in New York, from 2005 to 2006. Prior to Morgan Stanley, he worked at Bristol-Myers Squibb. Mr. Sun is also the chief executive officer of Sieger Healthcare Acquisition Corp., a special purpose acquisition company with no current business activities. Mr. Sun graduated from Vanderbilt University in the United States with a Bachelor of Science degree in chemistry in May 1998, obtained a Master of Arts degree majoring in pharmacology from Columbia University in the City of New York, United States, in October 2000, and graduated with distinction from New York University Stern School of Business in the United States with a Master of Business Administration degree in May 2005.